SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    John M. Murray, Ashish Goyal, In silico single cell dynamics of hepatitis B virus infection and clearance, Journal of Theoretical Biology, 2015, 366, 91

    CrossRef

  2. You have free access to this content2
    Jorg Petersen, Maura Dandri, Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?, Liver International, 2015, 35,
  3. 3
    Andrzej Taranta, Bui Tien Sy, Behrend Johan Zacher, Magdalena Rogalska-Taranta, Michael Peter Manns, Claus Thomas Bock, Karsten Wursthorn, Hepatitis B virus DNA quantification with the three-in-one (3io) method allows accurate single-step differentiation of total HBV DNA and cccDNA in biopsy-size liver samples, Journal of Clinical Virology, 2014, 60, 4, 354

    CrossRef

  4. 4
    Hung-Chih Yang, Jia-Horng Kao, Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance, Emerging Microbes & Infections, 2014, 3, 9, e64

    CrossRef

  5. 5
    Su-Ru Lin, Hung-Chih Yang, Yi-Ting Kuo, Chun-Jen Liu, Ta-Yu Yang, Ku-Chun Sung, You-Yu Lin, Hurng-Yi Wang, Chih-Chiang Wang, Yueh-Chi Shen, Fang-Yi Wu, Jia-Horng Kao, Ding-Shinn Chen, Pei-Jer Chen, The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo, Molecular Therapy—Nucleic Acids, 2014, 3, 8, e186

    CrossRef

  6. 6
    Wan-Long Pan, Jie-Li Hu, Yan Fang, Qiang Luo, Ge Xu, Lei Xu, Zhou-Hong Jing, Xue-Feng Shan, Yan-Ling Zhu, Ai-Long Huang, Allele-specific polymerase chain reaction for detection of a mutation in the relax circular DNA and the covalently closed circular DNA of hepatitis B virus, Journal of Virological Methods, 2013, 194, 1-2, 277

    CrossRef

  7. 7
    Masaru Enomoto, Akihiro Tamori, Shuhei Nishiguchi, Norifumi Kawada, Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential, Journal of Gastroenterology, 2013, 48, 9, 999

    CrossRef

  8. 8
    Maura Dandri, Marc Lütgehetmann, Jörg Petersen, Experimental models and therapeutic approaches for HBV, Seminars in Immunopathology, 2013, 35, 1, 7

    CrossRef

  9. 9
    William E. Delaney, Molecular virology of chronic hepatitis B and C: Parallels, contrasts and impact on drug development and treatment outcome, Antiviral Research, 2013, 99, 1, 34

    CrossRef

  10. 10
    Karin Krebs, Nina Böttinger, Li–Rung Huang, Markus Chmielewski, Silke Arzberger, Georg Gasteiger, Clemens Jäger, Edgar Schmitt, Felix Bohne, Michaela Aichler, Wolfgang Uckert, Hinrich Abken, Mathias Heikenwalder, Percy Knolle, Ulrike Protzer, T Cells Expressing a Chimeric Antigen Receptor That Binds Hepatitis B Virus Envelope Proteins Control Virus Replication in Mice, Gastroenterology, 2013, 145, 2, 456

    CrossRef

  11. 11
    Tassilo Volz, Lena Allweiss, Mounira Ben ḾBarek, Michael Warlich, Ansgar W. Lohse, Jörg M. Pollok, Alexander Alexandrov, Stephan Urban, Jörg Petersen, Marc Lütgehetmann, Maura Dandri, The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus, Journal of Hepatology, 2013, 58, 5, 861

    CrossRef

  12. 12
    Marc Lutgehetmann, Tassilo Volz, Anne Köpke, Tim Broja, Eike Tigges, Ansgar W. Lohse, Eberhard Fuchs, John M. Murray, Joerg Petersen, Maura Dandri, In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice, Hepatology, 2010, 52, 1
  13. 13
    Massimo Levrero, Teresa Pollicino, Jorg Petersen, Laura Belloni, Giovanni Raimondo, Maura Dandri, Control of cccDNA function in hepatitis B virus infection, Journal of Hepatology, 2009, 51, 3, 581

    CrossRef

  14. 14
    William S. Mason, Sam Litwin, Allison R. Jilbert, Immune selection during chronic hepadnavirus infection, Hepatology International, 2008, 2, 1, 3

    CrossRef

  15. 15
    Margarita Pardo, Javier Bartolomé, Vicente Carreño, Current Therapy of Chronic Hepatitis B, Archives of Medical Research, 2007, 38, 6, 661

    CrossRef

  16. 16
    Stephen Locarnini, William S. Mason, Cellular and virological mechanisms of HBV drug resistance, Journal of Hepatology, 2006, 44, 2, 422

    CrossRef

  17. 17
    Olivier Schorr, Christelle Borel, Christian Trepo, Fabien Zoulim, Olivier Hantz, Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes, Journal of Hepatology, 2006, 44, 5, 842

    CrossRef

  18. 18
    Volker Eckert, Wilhelm G. Struff, Hepatitis B: Where Are We Today?, Transfusion Medicine and Hemotherapy, 2006, 33, 5, 441

    CrossRef

  19. 19
    Maura Dandri, Tassilo Volz, Marc Lutgehetmann, Jorg Petersen, Modeling infection with hepatitis B virusesin vivo, Future Virology, 2006, 1, 4, 461

    CrossRef

  20. 20
    Karsten Wursthorn, Marc Lutgehetmann, Maura Dandri, Tassilo Volz, Peter Buggisch, Bernhard Zollner, Thomas Longerich, Peter Schirmacher, Frauke Metzler, Myrga Zankel, Conrad Fischer, Graeme Currie, Carol Brosgart, Joerg Petersen, Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B, Hepatology, 2006, 44, 3
  21. 21
    Anastasia Rivkin, A review of entecavir in the treatment of chronic hepatitis B infection, Current Medical Research and Opinion, 2005, 21, 11, 1845

    CrossRef

  22. 22
    Zhuhui Huang, Victor E. Buckwold, A TaqMan PCR assay using degenerate primers for the quantitative detection of woodchuck hepatitis virus DNA of multiple genotypes, Molecular and Cellular Probes, 2005, 19, 4, 282

    CrossRef

  23. 23
    M. Dandri, T.K. Volz, M. Lütgehetmann, J. Petersen, Animal models for the study of HBV replication and its variants, Journal of Clinical Virology, 2005, 34, S54

    CrossRef

  24. 24
    Maura Dandri, Jorg Petersen, Hepatitis B virus cccDNA clearance: Killing for curing?, Hepatology, 2005, 42, 6
  25. 25
    Fabien Zoulim, New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA, Journal of Hepatology, 2005, 42, 3, 302

    CrossRef

  26. 26
    Samuel Litwin, Eugene Toll, Allison R. Jilbert, William S. Mason, The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: Theoretical considerations, Journal of Clinical Virology, 2005, 34, S96

    CrossRef

  27. 27
    Yuao Zhu, John M. Cullen, Carol E. Aldrich, Jeffry Saputelli, Darren Miller, Christoph Seeger, William S. Mason, Allison R. Jilbert, Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus, Virology, 2004, 327, 1, 26

    CrossRef

  28. 28
    H. M. Younger, A. J. Bathgate, P. C. Hayes, Review article: nucleoside analogues for the treatment of chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2004, 20, 11-12
  29. 29
    Jianming Hu, David Nguyen, Therapy for chronic hepatitis B: the earlier, the better?, Trends in Microbiology, 2004, 12, 10, 431

    CrossRef

  30. 30
    Erwin Sablon, Fred Shapiro, Fabien Zoulim, Early detection of hepatitis B drug resistance: implications for patient management, Expert Review of Molecular Diagnostics, 2003, 3, 5, 535

    CrossRef

  31. 31
    P Honkoop, RA de Man, Entecavir: a potent new antiviral drug for hepatitis B, Expert Opinion on Investigational Drugs, 2003, 12, 4, 683

    CrossRef

  32. 32
    Stephen Locarnini, Hepatitis B viral resistance: mechanisms and diagnosis, Journal of Hepatology, 2003, 39, 124

    CrossRef

  33. 33
    Robert P. Perrillo, Hepatitis B: Treatment strategies for currently available drugs, Current Hepatitis Reports, 2003, 2, 2, 63

    CrossRef

  34. 34
    Y.-Y. Zhang, B.-H. Zhang, D. Theele, S. Litwin, E. Toll, J. Summers, Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver, Proceedings of the National Academy of Sciences, 2003, 100, 21, 12372

    CrossRef

  35. 35
    Jordan Feld, Stephen Locarnini, Antiviral therapy for hepatitis B virus infections: new targets and technical challenges, Journal of Clinical Virology, 2002, 25, 3, 267

    CrossRef

  36. 36
    William E Delaney IV, Angeline Bartholomeusz, Stephen A Locarnini, Evolving therapies for the treatment of chronic hepatitis B virus infection, Expert Opinion on Investigational Drugs, 2002, 11, 2, 169

    CrossRef

  37. 37
    Robert P. Perrillo, How will we use the new antiviral agents for hepatitis B?, Current Gastroenterology Reports, 2002, 4, 1, 63

    CrossRef

  38. 38
    Bernhard Zöllner, Jörg Petersen, Matthias Schröter, Rainer Laufs, Volker Schoder, Heinz-Hubert Feucht, 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw, The Lancet, 2001, 357, 9260, 934

    CrossRef

  39. 39
    Leonieke M. M. Wolters, Hubert G. M. Niesters, Robert A. de Man, Nucleoside analogues for chronic hepatitis B, European Journal of Gastroenterology & Hepatology, 2001, 13, 12, 1499

    CrossRef

  40. 40
    Souphalone Luangsay, Fabien Zoulim, Structure and Molecular Virology,